title: Comparison between crude interleukin-2 and recombinant interleukin-2 in maintaining killing activity of cultured lymphocytes.
abstract: Peripheral blood lymphocytes, regional lymph node lymphocytes or malignant effusion lymphocytes from cancer patients were incubated with crude IL-2 (cIL-2) for 13 days. These effectors, which frequently expressed IL-2 receptor (IL-2R), proliferated well and possessed augmented killing activity against fresh autologous tumor cells and K562. However, when recombinant IL-2 (rIL-2) was added for the last 4 days of culture instead of cIL-2, IL-2R expression and killing activity against fresh autologous tumor cells decreased significantly (P less than 0.05). Phenotypic analysis indicated that cIL-2 significantly promoted the expansion of the cytotoxic population (CD8+.11b-)(P less than 0.05). The decreases in killing activity and IL-2R expression were restored by 0.004% PHA plus rIL-2, but not in the presence of rIFN-gamma, rIL-1 alpha, rIL-1 beta, rIL-4 or rIL-6. PHA-free cIL-2 maintained killing activity, but not IL-2R expression. We conclude that some factors in cIL-2 and a low dose of PHA-P are necessary for the maintenance of killing activity and IL-2R expression of cultured lymphocytes in the late phase of culture.
authors.affiliation: First Department of Surgery, School of Medicine, Kyoto University, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Nakanishi
authors.forename: N
authors.initials: N
authors.lastname: Kan
authors.forename: T
authors.initials: T
authors.lastname: Okino
authors.forename: K
authors.initials: K
authors.lastname: Satoh
authors.forename: K
authors.initials: K
authors.lastname: Mise
authors.forename: Y
authors.initials: Y
authors.lastname: Teramura
authors.forename: S
authors.initials: S
authors.lastname: Yamasaki
authors.forename: K
authors.initials: K
authors.lastname: Ohgaki
authors.forename: T
authors.initials: T
authors.lastname: Tobe
mesh_terms: D002455:Cell Division / Q000187:drug effects; D002470:Cell Survival; D003602:Cytotoxicity, Immunologic / Q000187:drug effects*; D006801:Humans; D007371:Interferon-gamma / Q000494:pharmacology; D007376:Interleukin-2 / Q000494:pharmacology*; D007958:Leukocyte Count; D008213:Lymphocyte Activation / Q000187:drug effects*; D008214:Lymphocytes / Q000187:drug effects* / Q000276:immunology; D010835:Phytohemagglutinins / Q000494:pharmacology; D011994:Recombinant Proteins / Q000494:pharmacology; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects / Q000276:immunology; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000276:immunology*
chemical_list: D007376:Interleukin-2; D010835:Phytohemagglutinins; D011994:Recombinant Proteins; C028784:phytohemagglutinin-P; D007371:Interferon-gamma